- Home
- MGEE vs VERA Comparison
MGEE vs VERA Comparison
Compare MGEE & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGEE | VERA |
|---|---|---|
| Founded | 1855 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MGEE | VERA |
|---|---|---|
| Price | $84.23 | $41.49 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $80.50 | ★ $81.30 |
| AVG Volume (30 Days) | 309.9K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 11.71 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $2.77 | $472.48 |
| P/E Ratio | $61.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $72.16 | $19.07 |
| 52 Week High | $90.14 | $56.05 |
Technical Indicators
Market Signals| Indicator | MGEE | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 73.17 | 60.59 |
| Support Level | $80.98 | $37.54 |
| Resistance Level | $84.76 | $42.77 |
| Average True Range (ATR) | 1.86 | 2.16 |
| MACD | 0.69 | 0.77 |
| Stochastic Oscillator | 97.17 | 63.48 |
Price Performance
Historical ComparisonAbout MGEE MGE Energy Inc
MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.